1. HBW Insight
  2. >>Health
  3. >>Business
  4. >>Strategy

Sanofi Plans Further Consumer Health Divestments As It Reports Slow Start To Year

 
• By Tom Gallen

Sanofi tells investors to expect further Consumer Healthcare brand divestments in 2019 as it continues to rationalize its portfolio following the transformational acquisition of Boehringer Ingelheim's OTC business in 2017. As a result of divestments in 2018, as well as a number of seasonal factors, Sanofi reported a 0.6% rise in Consumer Healthcare's sales in Q1.

Two businessmen shaking hands during a meeting in the office, success, dealing, greeting & business partner concepts - soft light.
• Source: Shutterstock

Sanofi is not done pruning brands from its Consumer Healthcare portfolio as it seeks to better focus its resources on its four core product categories.

Addressing investors on the French firm’s first-quarter earnings call, CEO Olivier Brandicourt said the OTC brand divestments seen in 2018 would not be the last

Sanofi significantly expanded Consumer Healthcare in 2017 with the acquisition of Boehringer Ingelheim GmbH's Consumer Health Care business, adding a portfolio of brands – including Buscopan antispasmodics (hyoscine butylbromide), Dulcolax laxatives (bisacodyl), Mucosolvan cough and cold products (ambroxol) – which generated annual sales in excess of €1bn ($1.1bn)

More from Strategy

Danes Get OTC Access To ED Treatment

 
• By Tom Gallen

Navamedic has launched Eroxon in Danish pharmacies giving men in the country OTC access to an ED treatment for the first time.

Haleon Targets Low Income Households In Push To Reach 1bn More Consumers

 
• By Tom Gallen

Haleon wants to reach one billion more consumers by 2030 and plans to do this by tailoring products to those outside the highest income bracket. The UK-based firm's five-year growth plan will also see it generate £0.8bn in productivity savings.

People On The Move: Appointments At Haleon, Wellnex, Orkla

 
• By Tom Gallen

A round-up of the latest consumer health leadership changes: Haleon names Middle East & Africa unit manager; Wellnex Life appoints interim chair; Orkla Health appoints CEO.

Opella Goes Solo Promising To ‘Redefine The Future Of Self-Care’

 
• By Tom Gallen

Private equity firm CD&R takes control of Opella while Sanofi retains a sizeable stake and nets €10bn.

More from Business

Haleon Targets Low Income Households In Push To Reach 1bn More Consumers

 
• By Tom Gallen

Haleon wants to reach one billion more consumers by 2030 and plans to do this by tailoring products to those outside the highest income bracket. The UK-based firm's five-year growth plan will also see it generate £0.8bn in productivity savings.

People On The Move: Appointments At Haleon, Wellnex, Orkla

 
• By Tom Gallen

A round-up of the latest consumer health leadership changes: Haleon names Middle East & Africa unit manager; Wellnex Life appoints interim chair; Orkla Health appoints CEO.

Opella Goes Solo Promising To ‘Redefine The Future Of Self-Care’

 
• By Tom Gallen

Private equity firm CD&R takes control of Opella while Sanofi retains a sizeable stake and nets €10bn.